The vaccine consists of Live Attenuated Bacterial Vaccine to Reduce or Inhibit Carriage and Shedding of Enterohemorrihagic Escherichia Coli in Cattle. This vaccine was developed for use against Shiga toxin-producing E.Coli (STEC) in cattle. This strategy is to construct mutants that have deletion in the genes responsible for E.Coli O157:H7 toxicity. Along with the mutation to inactivate the Shiga toxin gene, the modified bacteria also carry a mutation that inactivates genes that allows the growth of the E.Coli 0157:H7 in the cow intestine. These modifications will greatly attenuate bacterial virulence.
According to Dr.
Their efforts are bolstered by the recent report from the Washington Post dated
Officials have assumed that these numbers reflect an overall increase in the prevalence of the E.Coli strain in cattle, but no one has been able to explain why the dangerous bacteria have become more abundant.
Given the recent emergence of a similar product from a competitor, we feel that now is the time to begin a full court press to bring our vaccine to the forefront of the agricultural and food industries. We believe very strongly that our vaccine is a far superior product to that of our competition.
To help bring awareness to GeneThera and its efforts, we have engaged two very well known multimedia investor relations firms, Wallst.net and StockBully.com.
Both firms are multimedia investor relation's sources that seek out promising and mostly undiscovered companies in the market place and enable their clients to utilize multimedia marketing to gain exposure via the information highway.
"GeneThera is a fantastic company with a solid business model and superior management. We are extremely pleased to have the opportunity to assist them in their effort to increase investor awareness in the financial market," said
About E.Coli O157:h7
There are a variety of Escherichia coli bacteria present in nature. They are usually found in the intestines of healthy humans and healthy animals. Even though these bacteria offer beneficial properties, there are those variations, or strains that are pathogenic (have the ability to cause disease). Escherichia coli 0157:H7 is one particular strain that is "... an emerging cause of food borne illness ..." Symptoms such as bloody diarrhea and abdominal cramps may be observed or no such symptoms may appear. The elderly and children under five years old are highly susceptible to Hemolytic Uremic Syndrome, a disease in which red blood cells are destroyed and kidneys fail.
According to the CDC "...there may be about 70,000 infections with E. Coli O157:H7 each year in
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Dr.
Goldsmith Group 303-838-4370
JR Dopkin & Associates 516-884-3200
SOURCE GeneThera, Inc.